Development of lipid-polymer hybrid nanoparticles via microfluidics, for the intracellular delivery of nucleic acid therapeutics.

   School of Pharmacy (Medway Campus)

This project is no longer listed on and may not be available.

Click here to search for PhD studentship opportunities
  Dr N Lavignac, Dr Vladimir Gubala  Applications accepted all year round  Self-Funded PhD Students Only

About the Project


A hybrid class of nanoparticles, aimed at combining the advantages of both polymeric nanoparticles and liposomes, has received attention in recent years. These core/shell type nanoparticles, frequently referred to as lipid-polymer hybrid nanoparticles (LPNs), possess several characteristics that make them highly suitable for drug delivery in the fields of cancer therapy and infectious diseases.

Microfluidics has been used to prepare a range of nanoparticles and alleviate some of the issues (e.g. poor reproducibility and polydispersity) encountered with the traditional bulk formulation. Nucleic acid therapeutics, such as DNA and RNA, can potentially achieve long-lasting effect. However, their clinical translation can be hindered due to issues such as poor stability and cellular internalization or non-specific target affinity.

The aim of this project is to develop novel lipid-polymer hybrid nanoparticles (LPNs), able to protect nucleic acid therapeutics from degradation and improving their intracellular delivery.

The work will include the development of microfluidics methodology to formulate LPNs using different natural or synthetic polymers and suitable lipids. Model and therapeutic nucleic acids will be encapsulated during or after the formulation of the nanoparticles. The synthesised nanoparticles will be characterised using different analytical techniques such as zeta, size distribution, SEM/TEM, UV/Vis. Loading efficiency, LPNs stability, and the capacity to protect nucleic acids will be investigated using established methods. The formulations with the most suitable physicochemical properties will be used to deliver model and pharmacologically active nucleic acids to relevant model cell lines (e.g cancer cells, macrophages).

Entry requirements

Applicants should have or expect to obtain a first or upper second class honours degree (or equivalent) in an appropriate subject and a Masters (at Merit or above) in Chemistry or closely related subject.


Informal enquiries should be made to Dr. Nathalie Lavignac ([Email Address Removed]; Tel: +44 (0)1634 202991). Applications should be in the form of a full C.V. and covering letter either emailed or sent to Dr. Nathalie Lavignac, Medway School of Pharmacy, University of Kent, Anson Building, Central Avenue, Chatham, Kent, ME4 4TB.

Chemistry (6) Engineering (12) Medicine (26)

Funding Notes

This project is a self-funded opportunity available to both Home/EU and International students.
Applicant must have access to funding to cover tuition fees, living costs and any related project costs (i.e. bench fees).

Where will I study?

Search Suggestions
Search suggestions

Based on your current searches we recommend the following search filters.